# US 2022/0033522 A1 · Materials and methods for multidirectional biotransportation in virotherapeutics

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0033522 A1
- Document ID: US20220033522A1
- Status: Published application
- Kind: A1
- Application number: 17/391,744
- Filed: 2021-08-02
- Published: 2022-02-03
- Earliest claimed: 2020-08-03
- Assignees: Janssen Biotech, Inc.
- Applicants: Janssen Biotech, Inc.
- Inventors: Rajkumar GANESAN; Adam ZWOLAK; Ian WHITE; Ninkka TAMOT; Paul B. HARVILLA; Rajitha DODDAREDDY; Sanjaya SINGH; Martin Jack BORROK III
- Web page: https://patentgrep.com/patent/US20220033522A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 14/005: from viruses
- C07K 16/10: RNA viruses
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- C07K 16/40: against enzymes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/524: CH2 domain
- C07K 2317/53: Hinge
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2317/71: Decreased effector function due to an Fc-modification
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/30: Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are multispecific molecules comprising a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR) and a second binding domain that specifically binds to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and related methods for the treatment of patients infected with SARS-CoV-2.

## Claims

### Claim 1

A multispecific molecule comprising: (a) a first binding domain that specifically binds to polymeric immunoglobulin receptor (pIgR), and (b) a second binding domain that specifically binds to a second target that is not pIgR;
wherein optionally the second target is SARS-CoV-2.

### Claim 2 (depends on 1)

The molecule of claim 1, wherein the molecule is a bispecific molecule.

### Claim 3 (depends on 1)

The molecule of claim 1, wherein the second binding domain specifically binds to the surface of SARS-CoV-2;
wherein optionally the second binding domain specifically binds to the spike glycoprotein on the surface of SARS-CoV-2;
and wherein optionally the second binding domain specifically binds to the S1 subunit of the spike glycoprotein on the surface of SARS-CoV-2.

### Claim 4 (depends on 1)

The molecule of claim 1, wherein the second binding domain comprises
(a) angiotensin-converting enzyme 2 (ACE2);
wherein optionally the ACE2 comprises the amino acid sequence of SEQ ID NO:194;
(b) the extracellular domain of ACE2;
wherein optionally the extracellular domain of ACE2 comprises an amino acid sequence of SEQ ID NO:134; or
(c) a truncated extracellular domain of ACE2;
wherein optionally the truncated extracellular domain of ACE2 comprises an amino acid sequence of SEQ ID NO:120, or
wherein optionally the truncated extracellular domain of ACE2 comprises an amino acid sequence of SEQ ID NO:121.

### Claim 5 (depends on 1)

The molecule of claim 1, wherein the first binding domain comprises a single-domain molecule (VHH); optionally wherein the VHH comprises
(a) a complementarity determining region 1 (CDR1) having an amino acid sequence of SEQ ID NO:1, a CDR2 having an amino acid sequence of SEQ ID NO:2, and a CDR3 having an amino acid sequence of SEQ ID NO:3: further wherein the VHH comprises an amino acid sequence of SEQ ID NO: 16; or
(b) a CDR1 having an amino acid sequence of SEQ ID NO: 17, a CDR2 having an amino acid sequence of SEQ ID NO:18, and a CDR3 having an amino acid sequence of SEQ ID NO:19; further wherein the VHH comprises an amino acid sequence of SEQ ID NO:32.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The molecule of claim 1, wherein the first binding domain specifically binds to pIgR that is present on the mucosal endothelium;
wherein optionally the first binding domain specifically binds to pIgR that is present on the lung mucosal endothelium.

### Claim 8 (depends on 1)

The molecule of claim 1, wherein the SARS-CoV-2 is neutralized when the molecule specifically binds to the pIgR and to SARS-CoV-2;
wherein optionally the molecule neutralized SARS-CoV-2 with an EC50 of (a) less than about 4 nM; (b) less than about 3 nM; (c) less than about 1 nM; (d) less than about 500 pM; or (e) less than about 100 pM.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

A molecule comprising: a first means capable of binding pIgR on the mucosal endothelium; and a second means capable of binding a second target on the surface of a second cell or on the surface of a virus; wherein optionally the virus is SARS-CoV-2.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15 (depends on 1)

A nucleic acid encoding the molecule of claim 1.

### Claim 16 (depends on 15)

A vector comprising the nucleic acid of claim 15.

### Claim 17 (depends on 16)

A host cell comprising the vector of claim 16.

### Claim 18 (depends on 16)

A kit comprising the vector of claim 16 and packaging for the same.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising the molecule of claim 1, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising the means for delivering the molecule of claim 1, and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 19)

A method of producing the pharmaceutical composition of claim 19, comprising combining the molecule with a pharmaceutically acceptable carrier to obtain the pharmaceutical composition.

### Claim 22 (depends on 1)

A method of inhibiting host cell entry or proliferation of target cells expressing the second target, the method comprising contacting the target cells with the molecule of claim 1, wherein contacting the target cells with the molecule inhibits host cell entry or proliferation of the target cells;
wherein optionally the second target is SARS-CoV-2.

### Claim 23 (depends on 1)

A method for eliminating target cells expressing the second target in a subject, comprising administering an effective amount of the molecule of claim 1 to the subject;
wherein optionally the second target is SARS-CoV-2; and wherein optionally the subject has COVID-19.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

A method of treating a disease caused all or in part by cells expressing the second target in a subject, comprising administering an effective amount of the molecule of claim 1 to the subject;
wherein optionally the second target is SARS-CoV-2; wherein optionally the disease is COVID-19.

### Claim 26

(canceled)

### Claim 27 (depends on 23)

The method of claim 23, wherein the subject is a subject in need thereof;
wherein optionally the subject is a human.

### Claim 28

(canceled)

### Claim 29

A process for making a molecule that specifically binds to more than one target molecule, the process comprising:
a step for performing a function of obtaining a binding domain capable of binding to pIgR on mucosal endothelium;
a step for performing a function of obtaining a binding domain capable of binding to a second target on a second cell or a virus; and
a step for performing a function of providing a molecule capable of binding to a pIgR antigen on mucosal endothelium and a second target on a second cell or a virus optionally wherein the step for performing a function of obtaining a binding domain capable of binding to a second target is repeated n times and further comprising n steps for performing a function of providing a binding domain capable of binding to a pIgR on mucosal endothelium and n number of target molecules, wherein n is at least 2.

### Claim 30

(canceled)

### Claim 31 (depends on 29)

The process of claim 29, wherein
(a) the second target is on the surface of the second cell or
(b) wherein the second target is on the surface of a virus; optionally wherein the virus is SARS-CoV-2.

### Claim 32

(canceled)

### Claim 33

(canceled)

### Claim 34 (depends on 29)

The process of claim 29, wherein the first binding domain specifically binds (a) a pIgR antigen; or (b) a pIgR epitope.

### Claim 35 (depends on 29)

The process of claim 29, wherein the second binding domain specifically binds (a) an antigen of the second target or (b) an epitope of the second target.

### Claim 36

(canceled)
